advertisement
11.3.3 Apraclonidine, brimonidine (6)
Showing records 1 to 6
Display all abstracts in classification 11.3.3 Apraclonidine, brimonidine
Search within classification 11.3.3 Apraclonidine, brimonidine19555 The acute morphologic changes that occur at the optic nerve head induced by medical reduction of intraocular pressure
Meredith SP; Swift L; Eke T; Broadway DC
Journal of Glaucoma 2007; 16: 556-561
19312 Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension
Mundorf T; Noecker RJ; Earl M
Advances in Therapy 2007; 24: 302-309
19371 Adverse effects of apraclonidine used in the diagnosis of Horner syndrome in infants
Watts P; Satterfield D; Lim MK
Journal of AAPOS 2007; 11: 282-283
19437 Neuroprotective effect of topically applied brimonidine tartrate 0.2% in endothelin-1-induced optic nerve ischaemia model
Aktaş Z; Gürelik G; Akyürek N; Onol M; Hasanreisoğlu B
Clinical and Experimental Ophthalmology 2007; 35: 527-34
19330 Alteration of retinal intrinsic survival signal and effect of α2-adrenergic receptor agonist in the retina of the chronic ocular hypertension rat
Kim HS; Chang YI; Kim JH; Park CK
Visual Neuroscience 2007; 24: 127-139
19574 Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%
Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC; Additivity Study Group
Ophthalmology 2007; 114: 1248-1254
